Article Versions Notes

Jiang Y, Liu L, Jiang Y, Li Z, Feng L, Zhuang X, Lin Z, Chen Q, Chen G, He J, et al. Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells. Pharmaceuticals. 2022; 15(11):1313. https://doi.org/10.3390/ph15111313

Jiang, Yuelong, Long Liu, Yirong Jiang, Zhifeng Li, Liying Feng, Xinguo Zhuang, Zhijuan Lin, Qiuling Chen, Guoshu Chen, Jixiang He, and et al. 2022. "Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells" Pharmaceuticals 15, no. 11: 1313. https://doi.org/10.3390/ph15111313

Jiang, Y., Liu, L., Jiang, Y., Li, Z., Feng, L., Zhuang, X., Lin, Z., Chen, Q., Chen, G., He, J., Li, G., Zha, J., & Xu, B. (2022). Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells. Pharmaceuticals, 15(11), 1313. https://doi.org/10.3390/ph15111313